News | May 03, 2011

Being Tall, Obese May Increase Risk of Deep Vein Blood Clots

May 3, 2011 – Being tall and obese may increase your risk for potentially dangerous blood clots, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

Obesity is a well-known risk factor for clots in deep veins (usually in the legs) and for pulmonary embolism, a clot in blood vessels of the lungs that can result in sudden death or strain on the heart. Together, the two conditions are called venous thromboembolism (VTE).

Compared with short (5 feet, 7.7 inches or less) and normal-weight men (body mass index < 25kg/m2), the age-adjusted risk of VTE was:

• 5.28 times higher in obese and tall men

• 2.57 times higher in normal-weight and tall men (at least 5 feet, 11.7 inches tall)

• 2.11 times higher in obese and short men

 

Compared with short (5 feet, 2.6 inches or less) normal-weight women, the age-adjusted risk of VTE was:

• 2.77 times higher in obese and tall women

• 1.83 times higher in obese and short women

• Not increased in normal-weight and tall women (more than 5 feet, 6 inches)

The amount of risk conferred by being both obese and tall was comparable to other known risk factors for VTE, including pregnancy, the use of oral contraceptives and carrying one gene for an inherited predisposition to clotting called Factor V Leiden.

"We believe that we observed the increased risk in tall and normal-weight men, but not women, because most women do not get sufficiently tall," said Sigrid K. Braekkan, Ph.D., senior study author and a researcher in the Hematological Research Group at the University of Tromso in Norway. "The risk may be present in very tall women, but there were too few to investigate this properly."

Researchers said more studies are needed to determine the mechanisms of the association between tall stature, excess weight and the combination on the risk of VTEs.

"In tall people the blood must be pumped a longer distance by the calf-muscle pump, which may cause reduced flow in the legs and thereby raise the risk of clotting," Braekkan said. "Understanding and preventing VTE is important because even the first occurrence may be fatal. Obesity, in combination with other VTE risk factors, has been shown to substantially increase the risk, so we wanted to assess the combined effects of tall stature and obesity."

The research team analyzed data from the Tromso study, which conducts periodic health surveys of adults 25-97 years old in the Norwegian town. Researchers collected height and obesity measures on 26,714 men and women followed a median of 12.5 years between 1994 and 2007. During that time, 461 VTEs occurred.

Obesity causes increased pressure in the abdomen, which may reduce the ability of the calf-muscle pump to return the blood from the legs. "Obesity is also linked to a state of constant low-grade inflammation, and inflammation may render blood more susceptible to clotting," Braekkan said.

Physicians should consider people's height and weight as they assess their overall risk for dangerous clots, researchers said.

"Since body height is not easy to modify, the most important thing is to stay slim, especially if you are tall," Braekkan said.

The researchers previously found a strikingly similar rise in clot risk along with height in American men, and believe that the height cut-offs would apply to Caucasian populations in other regions.

In the United States, more than 275,000 people each year are hospitalized with deep vein clots or pulmonary embolism, according to the American Heart Association.

The University of Tromso and the Northern Norway Regional Health Authority funded the study.

For more information: www.americanheart.org

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init